| Names | |
|---|---|
| Preferred IUPAC name | 2-acetyloxybenzoic acid |
| Other names | ASA Acetylsalicylsäure Acetysal Alka-Seltzer Ecotrin Bufferin Easprin Entrophen Empirin Zorprin |
| Pronunciation | /ˈæspɪrɪn/ |
| Identifiers | |
| CAS Number | 50-78-2 |
| Beilstein Reference | 635273 |
| ChEBI | CHEBI:15365 |
| ChEMBL | CHEMBL25 |
| ChemSpider | 2157 |
| DrugBank | DB00945 |
| ECHA InfoCard | 100.011.204 |
| EC Number | 205-122-8 |
| Gmelin Reference | 5276 |
| KEGG | C00907 |
| MeSH | D001241 |
| PubChem CID | 2244 |
| RTECS number | AU4200000 |
| UNII | R16CO5Y76E |
| UN number | UN1851 |
| Properties | |
| Chemical formula | C9H8O4 |
| Molar mass | 180.16 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.40 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.19 |
| Vapor pressure | 7.5 x 10^-6 mmHg (25°C) |
| Acidity (pKa) | 3.5 |
| Basicity (pKb) | pKb ≈ 13 |
| Magnetic susceptibility (χ) | -29.6×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.473 |
| Dipole moment | 1.90 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 165.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | −592.0 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3157 kJ mol⁻¹ |
| Pharmacology | |
| ATC code | B01AC06 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P102, P103, P264, P270, P301+P312, P330, P501 |
| Flash point | 250°C (482°F) |
| Autoignition temperature | 465 °C |
| Lethal dose or concentration | LD50 (oral, rat): 200 mg/kg |
| LD50 (median dose) | 200 mg/kg (oral, human) |
| NIOSH | N20230000 |
| PEL (Permissible) | PEL: 5 mg/m³ |
| REL (Recommended) | 0.01 mg/m³ |
| IDLH (Immediate danger) | IDLH: 3,000 mg/m³ |
| Related compounds | |
| Related compounds | Salicylic acid Acetanilide Methyl salicylate Phenacetin Ibuprofen Paracetamol (Acetaminophen) Sodium salicylate Diflunisal O-acetylsalicylic acid Choline salicylate |
| Property | Manufacturer Perspective |
|---|---|
| Product Name |
Aspirin IUPAC Name: 2-acetoxybenzoic acid |
| Chemical Formula |
C9H8O4 Process control tracks reaction completion through quantitative monitoring of salicylic acid conversion. |
| Synonyms & Trade Names |
Acetylsalicylic Acid, ASA Some regional markets specify distinctive trade names, especially in the pharmaceutical sector—technical and industrial grades typically use the generic name. |
| CAS Number |
50-78-2 Sourcing and downstream authentication require batch-level traceability back to this identifier for regulatory as well as customer auditing purposes. |
| HS Code & Customs Classification |
Typical classification: HS Code 2918210000 (Salicylic acid and its salts, acetyl derivatives). Classification may require subdivision according to intended use, finished dosage form, or derivative state—imports and exports are scrutinized through this code for compliance with drug precursor regulations. |
Aspirin manufacturing integrates acetylation of salicylic acid with acetic anhydride as the acetyl donor. The process grade specification varies: for direct pharmaceutical feedstock, impurity profiles face stricter limits; technical grades produced for intermediates or non-medical applications allow a wider range, subject to specific end-user requirements.
Compound identity remains subject to validation at each stage. High-purity pharmaceutical grades depend on careful raw material selection and in-process purification to minimize residual salicylic acid and process-related by-products. Differences in regional regulatory demands affect final composition standards, labeling, and documentation. Process consistency relies on batch tracking, validated process controls, and contaminant source analysis.
Batch-to-batch variation reflects process route, choice of reactant grade, and post-synthesis purification method. Production efficiency and impurity control depend heavily on reaction kinetics, conversion efficiency, and solvent recovery practices. Final material release aligns with both in-house QC methods and customer acceptance criteria, recognizing that shelf life, degradation pathways, and packaging requirements shift depending on grade and storage conditions.
Acetylsalicylic acid appears as a solid crystalline material. Most commercial grades yield a white to faintly off-white powder or small crystals, without notable odor except at higher temperatures or with hydrolysis. Melting point ranges vary, with general pharmaceutical grades requiring conformance above 135°C, but process-specific impurities or trace moisture can shift onset points. Manufacturers commonly deal with melting behaviors during drying, milling, and packaging to avoid sintering or cohesion.
Boiling as a decomposition reaction leads to product breakdown, which impacts process design; direct distillation is not relevant for industrial isolation. Density depends on crystal habit, particle size, and compaction history. Bulk densities, tapped and loose, are controlled by drying, milling, and screening steps, impacting downstream blending and tablet compression.
Aspirin undergoes slow hydrolysis in the presence of moisture, liberating salicylic acid and acetic acid. This decomposition is accelerated by elevated temperature and humidity. Industrial storage and transport require humidity and temperature management, otherwise hydrolysis degrades both efficacy and regulatory compliance. Certain metallic ions can increase decomposition rates, so contact with iron, copper, or basic packaging surfaces is avoided.
Solubility in water remains low under ambient conditions, but increases markedly at elevated temperature or under alkaline conditions. Solution for process testing or downstream application is best prepared under mildly acidic conditions to suppress premature hydrolysis. For industrial scale blending into formulations, particle size optimization supports uniform dispersion in poorly aqueous systems.
Commercial grades vary according to target market—pharmaceutical, technical, food additive, or reagent—each requiring adjustments in assay, residue on ignition, moisture, and heavy metal thresholds. Test methods align with monograph standards or customer-negotiated requirements, such as USP, EP, JP for pharma.
| Parameter | Pharmaceutical Grade | Technical Grade |
|---|---|---|
| Appearance | White crystalline powder | Off-white to white powder |
| Assay (purity, %) | Defined by pharmacopeia | Targeted by process specification |
| Moisture (%) | Specification driven by stability data | Set according to downstream use |
| Salicylic acid (impurity, %) | Strictly regulated | Process dependent |
Pharma grades require tighter control of heavy metals, organic volatile impurities, and bioburden. Technical grades may follow more relaxed impurity limits suitable for non-ingestible end uses.
Primary impurities include unreacted salicylic acid, acetic acid, and reaction by-products such as acetic anhydride-derived species. Moisture-accelerated hydrolysis raises salicylic acid content on storage, impacting quality release if not restrained. In-process monitoring focuses on controlling these through real-time sampling and titrimetric or chromatographic monitoring.
Release tests follow titration for assay, HPLC or TLC for impurity profiling, potentiometric or Karl Fischer for water content, and visual or instrumental approaches for color and clarity. Manufacturer-specific QC typically supplements standard compendial limits with internal performance targets to assure both compliance and manufacturability for downstream partners.
Salicylic acid and acetic anhydride represent the core raw materials. Sourcing emphasizes lot-to-lot consistency, with trace metal and organic contaminant control due to their potential to carry through or catalyze undesired reactions. Acetic acid or catalyst grade phosphoric or sulfuric acid may support reaction efficiency in some routes.
Industrial synthesis uses the acetylation of salicylic acid with acetic anhydride. Reaction routes can be batch or continuous, with solvent-free systems prioritized to limit waste and control downstream purification. Temperature carefully manages to favor conversion while limiting hydrolysis; by-product acetic acid is either distilled off or recycled according to facility design.
Process parameters—temperature, reaction time, pH—directly impact impurity levels. Water content in raw materials is minimized; any presence accelerates salicylic acid reformation. Post-reaction, filtration, crystallization, and washing remove unwanted by-products. Solvent selection for washing depends on the grade and regional environmental handling requirements. Drying must balance throughput and moisture control since overdrying supports product degradation.
Batch release follows multi-point sampling for both in-process control and finished product. Key control points include monitoring for residual starting material, by-product contamination, particle size, and moisture. Final release incorporates assay, related substances, and heavy metal tests, all referenced to internal batch master records and end-use requirements. Each facility may have proprietary tolerances based on equipment capabilities and prior statistical process validation.
Acetylsalicylic acid undergoes base- or moisture-catalyzed hydrolysis back to salicylic acid and acetic acid, especially under elevated temperature. Further chemical modification by esterification or salt formation creates derivatives used in other pharmaceutical applications, but each modification step introduces new impurity and stability challenges requiring fresh process control.
Catalysts (such as mineral acids) may enhance acetylation during manufacture, but subsequent purification steps ensure removal to acceptable levels for the targeted grade. Temperature and solvent conditions are tuned to maximize conversion, minimize degradation, and maintain manageable isolation of crystalline product.
Sodium acetylsalicylate, and certain prodrug esters, derive from acetylsalicylic acid but demand additional reaction sequences. Strict precursor quality translates directly to downstream performance, and any deviation has an observable effect on both conversion yield and stability.
Aspirin products require dry conditions, limited exposure to moisture, and temperature stabilization to prevent hydrolytic decomposition. Light exposure is less critical, but elevated humidity poses the greatest threat to shelf stability. Gas-phase protection—when specified—is product or region-specific. Polyethylene-lined drums or glass containers are favored for pharmaceutical grades given their minimal reaction potential. Technical grades may use bulk bags or fiber drums when reactivity controls allow.
Acetylsalicylic acid reacts with certain metal surfaces, generating colored degradation products or accelerating breakdown, justifying exclusion of aluminum and uncoated ferrous containers for high-purity applications.
Shelf life depends on grade, container integrity, and warehousing practices. Salicylic acid levels are monitored as an indicator of degradation during storage. Product exhibiting increased odor (acetic acid smell), color changes, or moisture clumping is isolated and assessed before further processing or usage.
Aspirin falls under "hazardous by ingestion and inhalation routes" in concentrated or bulk powder form. Final hazard labelings reflect particle size, dust-raising potential, and country-specific GHS interpretation.
Primary hazards in manufacturing settings include dust inhalation, eye or skin irritation, and accidental ingestion. Manufacturing staff use local exhaust and dust suppression, NIOSH or EN-rated masks, and routine area monitoring for cumulative residue.
Acute oral toxicity is well-documented from reference studies, but specific industrial handling focuses on managing chronic exposure, skin sensitization, and dust-related respiratory issues. Data on reproductive or systemic toxicity directs restricted use protocols only for personnel with relevant health screening.
Regulatory exposure limits are set by national authorities and can vary by jurisdiction and downstream application. Facility SOPs set internal monitoring below these levels, with medical surveillance for chronic exposure groups. Handling recommendations rely on maintaining process enclosures, regular cleaning cycles, and rapid mitigation of any bulk spills.
Aspirin production output depends on the configuration and throughput of acetylation lines and the consistency of salicylic acid and acetic anhydride feedstocks. Large-scale pharmaceutical-grade units operate with reactor systems optimized for multi-ton batch runs, while industrial grades can be produced on versatile multi-purpose lines. Output varies by planned maintenance schedules, local permit capacities, and utility reliability. During periods with upstream feedstock bottlenecks or regulatory audits, capacity is reserved for strategic contract volumes, sequence by forecast and annual contract commitments.
Typical lead times are set by campaign scheduling and QC release windows. For bulk orders tied to regular contracts, lead times routinely fall within two to four weeks from order confirmation, conditional on customer-specific testing protocols. Spot orders or custom grade requirements involve longer cycles due to changeover and sampling validation. MOQ is dictated by batch size, which varies with grade and packaging format. API-certified batches often carry a higher MOQ due to validation and documentation requirements.
Packaging depends on both customer process requirements and regulatory compliance. For industrial and API applications, powder is delivered in HDPE drums, fiber drums with liner, or FIBC super sacks. For export, UN-certified containers safeguard against contamination, moisture ingress, and cargo movement. Line flushing routines and product-conveyance controls apply for all packaging runs, especially on pharmaceutical-grade lots to minimize cross-contaminant risk.
Shipping terms can be FOB, CIF, or DDP, driven by regional customer policy and handling infrastructure. Export compliance reviews screen for end-use declarations and destination controls. Main routes ship through temperature-controlled containerized cargo, dictated by region. Terms of payment generally tie to volume and customer track record, with L/C or T/T in advance as common modalities for new account setups, and open credit reserved for legacy validated buyers.
Aspirin cost structure heavily tracks the price of salicylic acid (itself beholden to phenol and sodium hydroxide), acetylation reagents, and process utilities. Volatility in crude phenol prices, regulatory curbs on process chemical emissions, and region-specific energy price swings generate most sourcing instability. Changes in plant environmental requirements and utility rate spikes especially impact Asian production hubs.
Product price follows grade, defined by residual impurity content, batch lot traceability, and documentary validation. API and BP/USP/EP certified product commands a premium due to required GMP trace, full-batch analytics, and code-compliant packaging. Lower grade or technical applications tolerate broader impurity windows and offer downstream formulator flexibility at reduced cost. Sterile or injectable grades cost more due to validated aseptic lines and periodic authority audits.
Price stratification is strictest for pharmaceutical buyers. These users demand full chain-of-custody evidence for each lot, validated by audit. Industrial grades for non-medicinal synthesis or formulation tolerate higher residual moisture, bioburden, or trace process contaminants, creating wider price floors. Packaging carries its own regulatory cost weighting; non-standard or custom-labeled containers command extra recovery for line segregation and documentation.
Global demand for Aspirin remains robust, led by continued pharmaceutical sector need and periodic surges in industrial applications. Demand outstrips supply following regulatory shutdowns in large-volume producer countries or force majeure events affecting chemical value chains. The US and Europe retain steady consumption, with new capacity blooms visible in southeast Asia and India. Re-shoring trends in Japan and the EU indicate growing preference for traceable, local lots over imported generic material.
The US maintains high reliance on established domestic players for prescription-grade Aspirin. European buyers show sensitivity to new REACH compliance updates and prioritize batch-tested imports only from GMP-audited facilities. Japanese market pulls high-consistency, high-certification batches and tracks slightly higher average price per kg. India and China sustain large-scale upstream production, often for lower grade or technical uses, with intermittent price shocks from environmental clampdowns or feedstock rationing.
Into 2026, price forecasts project upward pressure linked to stricter emissions controls in key Asian supply centers, tighter feedstock supply on the back of global phenol market turbulence, and expanded documentation cost from new cross-border pharmaceutical supply requirements. Domestic regulatory tightening in India and EU environmental levies weigh on export competitiveness. Publicly available data sets from ICIS, ChemData, and industry association tracking offer month-to-month trend confirmation; internal manufacturer contracting outcomes and customer feedback remain primary forward price indicators.
Recent quarters have seen production reallocation by major Asian manufacturers as local authorities intensified onsite inspections and environmental supervision, temporarily curbing available export lots. Strategic buyers advance order timelines or expand safety stock coverage to insulate against supply interruptions. Some Western buyers now phase dual supplier qualification to secure risk-mitigated supply.
Updated GMP and cross-border movement standards have driven API producers to adopt more rigorous batch certification, full batch record retention, and expanded audit windows. A shift towards digitally documented lot traceability aligns with newer international requirements, increasing both compliance time and certification cost.
Producers address volatility by diversifying raw material sources, investing in closed-loop solvent recovery to reduce emissions exposure, and integrating in-process analytics to maintain batch release schedules even during supply chain turbulence. Ongoing customer engagement now centers on shared risk stockpiling and advance ordering to anticipate probable regulatory or logistical disruptions.
As an aspirin manufacturer, production focuses exclusively on technical, pharmaceutical, and synthesis-use grades. The application field directly pulls from process capability and regulatory compliance. Pharmaceutical-grade acetylsalicylic acid follows stricter validation on impurity profiles, especially salicylic acid residuals and heavy metals, due to their relevance in direct human exposure. Synthesis and technical grades find placement in dye intermediates, polymerization catalysts, and agricultural chemical synthesis, where purity profiles and regulatory constraints differ. Pharmaceutical and synthesis-grade batch management shifts according to the primary user segment.
| Primary Application | Typical Grade | Critical Quality Parameters |
|---|---|---|
| Pharmaceutical Formulation (tablets, powders) | Pharmaceutical Grade | Purity, trace organics, particle size, microbial control |
| Bulk Synthesis (API intermediates, laboratory use) | Synthesis Grade | Purity, moisture content, specific impurities, solubility |
| Technical & Industrial Processing (chemical reagents, agricultural blends) | Technical Grade | Assay, residual solvents, non-critical impurities |
Each sector calls for a tailored approach:
Clarify if use sits within pharmaceutical, synthesis, or technical channels. End-application details drive risk assessment during manufacturing and guide selection of in-process control strategies. Final performance and regulatory risk depend on vividly defining the real-world endpoint for the material.
Review the framework governing your sector: pharmaceutical applications usually reference pharmacopeial standards while non-pharma channels defer to industry guidelines or internal specifications. This choice dictates batch release thresholds — especially for API and high-purity intermediates. Regions differ in documented limits and validation approaches, so plant SOPs match grade allocation to local regulatory climates.
Pharmaceutical customers generally set the tightest impurity and trace contaminant thresholds. Impurity source mapping begins at the raw ingredient procurement step — differing supply traces and synthetic routes alter by-product profiles. Purification requires matching to the intended market: high-performance columns and crystallization cycles become cost-justified for pharma supply. Less demanding technical applications often permit direct use post-filtration and drying, provided the batch meets the necessary chemical assay and impurity window.
Large-scale pharmaceutical production runs justify intensive QA/QC overhead and higher per-kilo costs for documentation, reprocessing risk, and compliance management. Industrial synthesis or agricultural blending might accept wider specification ranges if performance remains consistent at scale. Batch size directly affects both changeover dynamics at the plant and the pragmatic choice of campaign versus continuous production lines.
Process validation with supplied samples often surfaces end-use incompatibilities not always reflected in specification sheets. A typical practice at the manufacturing level involves providing representative pre-shipment lots drawn from full-scale production, not pilot or laboratory batches, due to batch-to-batch process variation in factors like particle size, water content, or color. Ongoing customer QC feedback loops inform future batch modifications or intra-grade customizations.
From sourcing to final release, every lot of aspirin passes through process controls and batch traceability monitored under independently certified management systems. Our manufacturing plants maintain ISO 9001 certification, allowing us to document each process step from incoming salicylic acid and acetic anhydride selection to tablet compression or bulk substance release. Annual audits, internal training, and digital batch logs support consistent process conditions and robust root-cause investigations for deviations. Customers requiring GMP or ICH Q7 compliance for pharmaceutical supply can request detailed certification scope and audit history. Certification status for each site reflects regional regulations and downstream application needs.
Pharmaceutical and food-grade aspirin output is tied to product-specific certification. For direct API supply, manufacturing is matched to validated processes and validated cleaning programs, with change control and reference standards per ICH guidelines. Certificates of Analysis (COA) include assay, related substances, residual solvents, and microbial data, aligned to the final product grade and pharmacopeial standard specified (such as USP, Ph. Eur., or JP). For food and feed applications, compliance aligns with HACCP and food additive grades, detailing allergen, GMO, and heavy metal controls per customer or market-specific regulations.
Full supporting dossiers are available to qualified partners, comprising method validation, stability data, certificates of origin, and shipping documentation according to regional requirements. Ongoing supply includes product quality review reports, change notifications, and supply chain traceability. Customers operating under regulatory or QMS frameworks receive direct shipment batch documentation with every delivery.
Our integrated production assets manage raw material procurement, multi-step synthesis, and purification on a backbone of continuous process monitoring. Regular preventive maintenance and aligned backup utilities contribute to dependable annual output determined by dedicated line allocation. Clients with forecasted or variable requirements can work with our production planning to establish firm delivery horizons or rolling call-off orders, structured around seasonal or market-driven volume swings. Priority is given to long-term partners with critical or regulated market needs, and contract manufacturing can be discussed for differentiated grades or purity ranges.
Core installed capacity supports regular API supply for multinational pharmaceutical manufacturers, with the ability to scale dedicated blocks for sudden market upticks or portfolio expansions. Parallel production trains and validated equipment redundancy limit downtime risk. For clients in regions with exports or logistics constraints, supply chains are adapted through multi-point distribution, and inventory planning tied to safety stock or on-site consignment models can be explored in negotiation.
Sample requests are managed according to intended use and grade sensitivity. Applicants specify intended application—pharmaceutical, food, technical—so that sampling respects regulatory requirements and contamination risks. Standard laboratory samples are provided with full compositional and impurity profiles as per the grade and current production lot. Requests for larger scale product development lots can be arranged, with associated non-disclosure agreements if formulation or intellectual property support is needed.
Flexibility in cooperation extends from custom pack sizing (from kilo to FIBC) to rolling volume agreements, consignment stock at customer warehouses, and contractual formulations aligned with downstream processing needs. For clients with proprietary processes, toll manufacturing options are reviewed case-by-case following a technical assessment of impurity risk and equipment compatibility. Core quality controls remain in place regardless of batch size or delivery mode. Multi-year framework agreements with guaranteed volume, revalidation triggers, and technical support can be established for strategic partners with cross-region business models or evolving quality/regulatory requirements.
Production, process safety, and impurity profile management continue driving technical discussion in the aspirin industry. Current laboratory studies examine green acetylation routes to reduce acetic anhydride excess and limit environmentally regulated byproducts. Switching to bio-based or recycled starting materials is under active evaluation, especially where regulatory frameworks require demonstrable reductions in fossil-based inputs. The suitability of solvent replacement and effective recovery strategies remain central R&D issues due to both environmental and cost pressures. Researchers closely monitor salicylic acid sourcing, as fluctuations in upstream quality directly influence the impurity management protocols for downstream aspirin batches.
Pharmaceutical grades maintain firm market dominance, but specialty and high-purity classes gain relevance as advanced formulation demand rises in both over-the-counter and regulated prescription markets. Analytical method optimization for trace impurities, including salicylic acid, phenol, and colored bodies, underpins the advancement of grades required for pediatric, geriatric, or sensitive clinical applications. Interest in non-oral delivery methods such as transdermal patches creates additional purity and physical stability standards that differ from bulk direct-compression tablets. Industrial grades, though stable in volume, now see closer scrutiny regarding allowable nitrosamine content and processing residues, which comes as regulatory landscapes tighten in key markets.
Achieving high batch consistency and minimizing batch-to-batch color variation often presents a challenge during scale-up. The main sources of technical difficulty stem from trace catalyst or iron carryover, process water contamination, and residual unreacted acid. Manufacturers focus on downstream purification—activated carbon, crystallization, and filtration best practices—to stabilize sensory and chemical quality. Advances in integrated PAT (process analytical technology) support real-time release strategies, shortening QA release timelines without relaxing batch scrutiny. Successful impurity reduction and trace residue management report breakthroughs through parallel process step optimization versus downstream reprocessing alone.
The global aspirin market expects stable near-term volume, with incremental gains projected in Asia and emerging regulated markets. New pharmacopoeial standards and regulatory tightening drive upgrades in both process documentation and impurity profiles to support long-term supply chain resilience. Shifts towards “pharma for pharma” alliances encourage information sharing regarding trace formation pathways and impurity trending data across the value chain. As public sector tenders grow more significant in setting product volume and quality floor, manufacturers invest in audit readiness and supply chain transparency beyond minimum GMP requirements.
Manufacturers focus on continuous-flow process deployment to reduce cycle times and enhance safety in acetylation stages. Inline analytics and feedback control facilitate rapid intervention at control points, which allows for tighter control of salicylic acid conversion, acetylation efficiency, and burnout of peroxide-forming contaminants. Digital plant management systems help coordinate real-time energy use and waste minimization, which brings the technical plant backbone closer in line with evolving sustainability benchmarks and customer reporting requests. Closed-loop solvent recovery, internal water reuse, and solventless process options receive growing capital investment.
Product stewardship depends increasingly on the traceability of raw materials and minimization of persistent organic residues. Aspirin process engineers now take a lifecycle view: minimized acetic acid emissions, use of renewable input chemicals, and compliant wastewater management across all plant operations. The push for “green” reaction media and recycling acetylating agents leads to more robust solvent handling and less toxic secondary waste streams. Production teams track and verify environmental footprint data for tenders and regulatory dossiers, with a strong emphasis on third-party verification for green claims.
Quality control and technical specialists advise downstream users on grade selection, batch fit-to-purpose assessment, and specific impurity or stability requirements. Regular batch lot documentation and cross-comparison support allow direct troubleshooting with formulation and regulatory teams. Upon request, in-process data and out-of-spec investigation records can be shared to support both regulatory filings and production troubleshooting. End-use technical consultation extends to support on storage, shelf-life prediction (if available), and compounding compatibility for advanced dosage forms.
Process engineers assist with customized advice on blending protocols, moisture sensitivity, particle handling, and cleaning strategies for equipment in line with the intended product application. When requirements shift towards non-tablet delivery systems, technical support includes guidance on alternative excipient compatibility and physical processing. Customers with specific trace impurity limits or alternative analytical method requirements receive batch-by-batch support and collaborative review of internal analytical data packages.
Batch recalls, deviation investigations, and continuous improvement reports form the backbone of ongoing after-sales support. Long-term customers receive tailored technical monitoring—trend analysis of shipment data, stability trending, and early-warning alerts based on agreed performance metrics. Manufacturers honor commitments through transparent batch audit trails, direct access to technical production staff, and prompt resolution of supply chain or product performance issues in close technical collaboration with the customer’s own quality assurance team.
As a chemical manufacturer specializing in acetylsalicylic acid, the full pathway from raw material assay to final packaging falls under our direct oversight. The acetylation process in our reactors offers precise control over the degree of purity, free acid content, and trace impurity profile. By maintaining stable reaction parameters and rigorous purification steps, we keep typical batches within a narrow specification range required by industrial customers. Large-scale, continuous batch operation strengthens process efficiency and limits lot-to-lot variability.
Large-volume pharmaceutical formulators, veterinary medicine producers, and intermediate chemical synthesis operations rely on a steady supply of aspirin meeting critical specification endpoints. Aspirin’s salicylate backbone supports various downstream applications, ranging from classic tablet production to non-steroidal intermediates. Our material is built for further processing, granulation, or liquid blending in high-throughput environments. The ability to guarantee specification compliance with each shipment reduces downstream technical risk for manufacturing clients.
Active ingredient production at scale only delivers value when process reliability stands on proof, not guesswork. Each lot undergoes validated chromatographic analysis, water content determination, and heavy metals screening. Sample retention practices and full production traceability enable batch re-verification and rapid response to technical inquiries from industrial partners. In-process quality records support internal decision-making and customer audits alike.
Large commercial accounts in pharmaceutical and specialty applications operate on just-in-time and volume-based models. We ship acetylsalicylic acid in high-integrity, moisture-repellent packaging: lined fiber drums, bulk bags, or custom container sizes requested by major producers. High-throughput warehouses and coordinated supply chain management shrink lead times and sustain delivery even during market upswings. Product protection and inventory reliability guide our logistics approach, supporting smooth plant operations for downstream users.
Our technical and application specialists work directly with customer process engineers and procurement managers to resolve process questions and address application challenges. Experience from chemical synthesis and pharmaceutical finished goods translates into practical assistance with blending, dissolution, and granule flow. The close link between our operations and customers’ R&D or quality units supports joint problem-solving in the field.
Direct-from-source production keeps cost structures transparent and supply lines short, maximizing value for high-volume industrial, pharmaceutical, and distribution channel partners. Bulk shipment volumes, repeat order stability, and a unified technical point of contact all contribute to lower operational risk. Our long-term focus on chemical synthesis, practical packaging options, and total quality accountability defines our approach to the commercial client relationship.
In industrial manufacturing, precise control over synthesis and formulation of acetylsalicylic acid assures a product that performs predictably in clinical settings. Aspirin has a simple core: acetylsalicylic acid, which acts by blocking the enzyme cyclooxygenase (COX). This process reduces the production of prostaglandins – compounds responsible for inflammation, pain, and fever. Our production follows time-tested protocols to maximize consistency in purity and content uniformity. When aspirin reaches the bloodstream, it irreversibly acetylates both COX-1 and COX-2 enzymes. This action not only reduces pain and brings down fever, it also affects platelets, which explains the role aspirin plays in helping to prevent blood clots.
From raw ingredient to finished tablet or bulk API, we focus on physical and chemical parameters verified by batch analytics. Once ingested, acetylsalicylic acid is absorbed rapidly through the stomach and upper small intestine. Maximum plasma concentrations typically occur within 30 to 60 minutes after oral dosing. Absorption speed links directly to particle size and crystal habit, both of which are controlled during our crystallization and milling steps. This ensures each batch dissolves efficiently in the body for predictable onset of action.
First-pass hydrolysis in the liver and circulating blood converts much of the acetylsalicylic acid to salicylic acid. Both actives circulate in the plasma, but only the parent compound delivers the COX-1 platelet inhibition that has made aspirin central in cardiovascular applications. Understanding this profile allows our technical team to support partners in product development, whether for immediate-release pain relief or enteric-coated forms designed to reduce stomach irritation.
We manufacture with an eye on the broader safety and performance profile, knowing that both acetylsalicylic acid and its major metabolite, salicylic acid, undergo conjugation in the liver before elimination via the kidneys. At lower doses, metabolism follows first-order kinetics, but as blood levels rise, pathways become saturated and zero-order kinetics begin to predominate. Manufacturers see the outcome of this phenomenon in extended plasma half-life with higher or chronic dosing, a key consideration for long-term cardiovascular regimens and one that influences our research into controlled-release formats.
Downstream effects of precise acetylsalicylic acid control matter to formulators and clinicians alike. We pay close attention to impurity profiles, particle size distribution, and uniformity within each drum or bag of finished product. These factors shape consistency from one tablet to the next or blend to blend. Our quality systems safeguard against issues that could impact absorption, efficacy, or side effect risk.
We provide acetylsalicylic acid for both pharmaceutical and industrial uses, making sure each delivery matches technical requirements, whether aimed at human health or specialized synthesis. Proven reproducibility underpins long-term supply partnerships and innovation in dosage forms. As a direct manufacturer, we offer access to technical data, COA, and support throughout the product’s global supply chain. Aspirin’s mechanism and pharmacokinetics set the expectations. Our process ensures those expectations are met, batch after batch.
Hospitals and healthcare institutions often look for pharmaceutical ingredients in larger volumes to sustain their operations and manage supply chain costs. Acetylsalicylic acid, known as aspirin, remains one of the most prescribed and administered medicines in global healthcare. Our plant produces acetylsalicylic acid at commercial scale, understanding the strict requirements that institutions demand for both volume and safety.
Bulk packaging for pharmaceutical ingredients such as acetylsalicylic acid involves much more than increasing box sizes. Large hospitals and centralized pharmacy services require packaging that supports both efficiency and compliance. Our bulk packaging conforms to pharmaceutical-grade standards. Typical shipping sizes for the active ingredient include fiber drums and high-density polyethylene containers, sealed with tamper-evident closures. Most hospital pharmacies order at scales of 25 kg, 50 kg, or even up to 200 kg per drum, designed to streamline receiving and repacking in sterile zones.
Within our production process, we ensure every drum is lined to prevent contamination. Products ship with traceable batch labels and corresponding certificates of analysis. Each lot can be traced at the raw material and finishing stage, critical for compliance and quality assurance in hospital purchasing protocols. No cutting corners, no unmarked or generic sacks—just fully identified and tightly sealed packaging that can go directly into institutional inventory.
Bulk acetylsalicylic acid serves as the foundational active material for hospital compounding and tablet pressing units. Hospitals ordering directly from a manufacturer get fresh, high-purity product with every order. Exposure to oxidation or humidity reduces shelf life and impacts pharmaceutical outcomes. We manage moisture barriers and physical protection from the filling line to shipment, supporting hospital requirements for stability and longevity.
Our technical team monitors regulatory updates for pharmaceutical excipients and actives. Each batch reflects adherence to pharmacopeial specifications, including particle size, purity, and appearance. Hospitals do not have to second-guess quality or risk mix-ups with subpar lots from unofficial sources. Our strict production line controls and clean environment standards underpin every shipment. In addition, we can provide detailed specifications, typical analyses, and records for institutional procurement review and internal audits.
Critical hospital supplies, especially for pain management and cardiology, need predictable availability. Disruptions occur when upstream suppliers blend stocks or rebrand material with ambiguous origin. By working directly with our facility, hospital procurement teams get supply-chain transparency and technical support. Logistics are optimized to protect the material during transit and storage, reducing waste and returns because of packaging failure or environmental exposure.
Drug recall events and compliance audits demand fast and accurate information traceability. Our batches include serialized shipment documentation, so hospitals can produce chain-of-custody instantly. For institutional buyers, consistent quality, optimized storage, and compliance with current regulations remain non-negotiable. We design our packaging and processes to support those priorities, with staff available to address any special technical needs that arise in large-scale public health settings. We continue to refine our processes with hospital pharmacy partners, focusing on reliability, compliance, and hospital workflow efficiency.
Aspirin, listed chemically as acetylsalicylic acid, forms a substantial part of our daily pharmaceutical production. Each batch clears a battery of internal quality checks before release to the logistics chain. While acetylsalicylic acid does not meet the international definitions for hazardous materials like strong toxics, corrosives, or flammables, established regulatory guidelines still shape how we store, handle, and transport finished goods and intermediates.
Day-to-day, raw acetylsalicylic acid and compressed aspirin tablets wait in sealed, moisture-proof packaging inside climate-stable storerooms. Direct sunlight accelerates degradation, leading to increased salicylic acid content—the whole reason our process automation tracks temperature and humidity continuously. From routine stability monitoring, we maintain storage between 15°C and 25°C, rarely allowing excursions past these targets. Any deviation triggers an internal review and corrective protocol. We document batch movement to keep chain of custody unambiguous for regulatory and customer audits alike.
Bulk acetylsalicylic acid and formulated tablets typically travel in fiber drums, HDPE containers, or lined carton boxes from our facility. Vehicles providing temperature insulation reduce the risk of quality loss during seasonal extremes. Routine cargo audits keep transporters aligned with Good Distribution Practice guidelines, focusing on clean, contamination-free compartments. Only vehicles with verified cleaning records get assigned to pharmaceutical runs. We refuse mixed-payload shipments involving strong oxidizers, acids, or volatile chemicals.
Our logistics team receives standardized training on particulate control, spillage prevention, and proper PPE use. Aspirin dust can irritate eyes, mucous membrane, and skin on direct exposure. Every shift starts with a refresher on safe drum opening procedures and prompt clean-up for accidental dispersion. Gowning, gloves, masks, and eye protection are non-negotiable standards—for our factory floor as well as warehouse teams. Material transfers utilize closed systems wherever feasible. All handling operations feature well-marked spill kits and rapid-deployment safety information placards.
We do not base our procedures on speculation—current pharmacopoeial standards drive every step. Each domestic and export shipment departs with up-to-date safety data sheets, certificates of analysis, and transport declarations if requested. Major markets inspect for compliance with drug master file registration, as well as Conformité Européenne (CE), United States Pharmacopeia, or local specifications. Our documentation process withstands audits by health authorities and global regulatory agencies without interruptions or nonconformance remarks. Custom declarations and import/export filings reference international requirements for pharmaceuticals, never relying on assumptions or informal shortcuts.
Even though acetylsalicylic acid stands a lower risk profile compared to solvents or controlled precursors, lax temperature control or contaminant ingress create significant downstream issues for formulators and healthcare providers. We have responded to past disruption by bolstering shipment monitoring along the entire route: electronic data loggers, GPS-based route tracking, and photo-verifiable cargo seals produce an end-to-end record for every customer. If a deviation arises, immediate notification follows along with a replacement batch—no delays or excuses. This model leads to less wastage, higher confidence from audit teams, and a record of zero transport-related recalls during the past five years. Ultimately, strict adherence to robust, science-based workflows secures both patient safety and customer trust.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
